Skip to main content

Publications, References, and Further Reading

Primary publication​

APASI: Automatic Psoriasis Area and Severity Index​

Mac Carthy T, Dagnino D, Medela A, Fernández G, Aguilar A, Martorell A, Gómez-Tejerina P, Roustán-Gullón G “Artificial Intelligence-Based Quantification to Assess the Automatic Psoriasis Area and Severity Index” JEADV Clinical Practice. 2025. doi:10.1002/jvc2.70143

JEADV Clin Pract. 2025

  • APASI provides a robust AI-driven framework for psoriasis severity assessment
  • Delivers rapid, objective, and precise evaluations of all PASI components
  • Integration into clinical and research workflows enhances disease monitoring
  • Reduces evaluation costs compared to manual multi-reader assessments

This is the foundational publication for the automated PASI scoring methodology, published in JEADV Clinical Practice.

Image quality assessment​

DIQA: Dermatology Image Quality Assessment​

Hernández Montilla I, Mac Carthy T, Aguilar A, Medela A “Dermatology Image Quality Assessment (DIQA): Artificial intelligence to ensure the clinical utility of images for remote consultations and clinical trials” Journal of the American Academy of Dermatology. 2023. doi:10.1016/j.jaad.2022.11.002

J Am Acad Dermatol. 2023;88(4):927-928

  • Pearson correlation ≥0.70 with expert image quality assessment
  • Real-time evaluation of focus, lighting, framing, and resolution
  • Critical for standardising image quality in multi-center psoriasis trials

DIQA is particularly important for psoriasis full-body imaging, where lighting consistency and framing quality directly impact the accuracy of erythema assessment and BSA segmentation.

Conference presentations​

AEDV (Spanish Academy of Dermatology and Venereology) 2025, Valencia

Oral communication: AI-based quantification to assess the automatic area and severity index of psoriasis

Oral presentation of the APASI methodology — automated PASI scoring via AI-driven quantification of erythema, desquamation, induration, and body surface area from clinical images.

EADV (European Academy of Dermatology and Venereology) 2025, Paris

Poster: APASI: Automatic Psoriasis Area and Severity Index with AI-driven quantification

Scientific poster presenting the APASI system — automated PASI scoring with component-level validation against expert inter-rater variability, demonstrating non-inferiority across all four PASI components.

Key references from the literature​

Fredriksson T, Pettersson U “Severity assessment of psoriasis in an international cross-sectional study” Dermatologica. 1978.

Original publication defining the PASI scoring system. Establishes the four-region, three-component methodology that remains the standard for psoriasis clinical trials.

U.S. Food and Drug Administration “Psoriasis: Developing Drug Products for Treatment. Guidance for Industry.” FDA Guidance Document. 2022.

FDA guidance establishing PASI 75/90/100 response rates and IGA as the primary endpoints for psoriasis drug development.

Clinical validation portfolio​

Legit.Health maintains an active clinical validation program across all supported conditions. The complete evidence portfolio is available in the clinical validation section.

Get started

AI-powered dermatology validated by peer-reviewed research. Trusted by leading hospitals across Europe. Fill in the form to see how our CE-marked platform can transform your practice.